Chicago Capital Doubles Down on PROCEPT BioRobotics, Adds $27 Million in Stock

1 hour ago 4

Josh Kohn-Lindquist, The Motley Fool

Fri, April 24, 2026 astatine 11:11 AM CDT 4 min read

According to a filing with the Securities and Exchange Commission dated April 23, 2026, Chicago Capital, LLC accrued its holding successful PROCEPT BioRobotics Corporation (NASDAQ:PRCT) by 969,592 shares from the erstwhile quarter. The estimated worth of the shares acquired is $27.32 million, calculated utilizing the mean unadjusted closing terms for the archetypal 4th of 2026. At the extremity of the quarter, the position's full worth was $54.04 million.

Chicago Capital accrued its involvement successful PROCEPT BioRobotics, bringing the presumption to 1.46% of its 13F reportable AUM

  • Top holdings aft the filing:

    • Alphabet: $212.79 cardinal (5.7% of AUM)

    • Meta Platforms: $162.41 cardinal (4.4% of AUM)

    • Amazon: $153.49 cardinal (4.1% of AUM)

    • Nvidia: $136.76 cardinal (3.7% of AUM)

    • Taiwan Semiconductor Manufacturing: $132.37 cardinal (3.6% of AUM)

As of April 23, 2026, PROCEPT BioRobotics shares were priced astatine $24.24, down 56.5% implicit the past year, underperforming the S&P 500 by 91 percent points.

Metric

Value

Price (as of marketplace adjacent 2026-04-23)

$24.24

Market capitalization

$1.37 billion

Revenue (TTM)

$308.05 million

Net income (TTM)

($95.57 million)

PROCEPT BioRobotics:

  • Develops, manufactures, and sells the AquaBeam Robotic System and Aquablation therapy for minimally invasive urologic surgery, chiefly targeting benign prostatic hyperplasia (BPH).

  • Generates gross done income of robotic systems, recurring consumables, and related services to healthcare providers.

  • Serves hospitals, ambulatory country centers, and urology practices, with a superior absorption connected the U.S. marketplace and expanding planetary presence.

PROCEPT BioRobotics Corporation is simply a surgical robotics innovator specializing successful urology, focusing connected image-guided, minimally invasive solutions for benign prostatic hyperplasia. The institution leverages a recurring gross exemplary done strategy income and ongoing consumable usage, supporting a increasing installed basal successful the United States and prime planetary markets. This strategy positions PROCEPT BioRobotics to capitalize connected the increasing request for advanced, less-invasive urologic treatments.

PROCEPT BioRobotics banal is down 76% from its all-time acceptable successful 2024, and Chicago Capital is pouncing connected the discounted shares. The steadfast has bought PRCT shares successful 7 of the past 8 quarters arsenic the banal declined from $80 to $25. As an up-and-coming, but inactive unprofitable stock, volatility similar this is communal among aesculapian instrumentality and attraction companies arsenic they archetypal person to beryllium their efficacy and past physique a concern astir their treatment.

Read Entire Article